A prospective observational study to assess the utility of comprehensive genomic profiling in patients with non-small cell lung cancer without driver genetic alterations
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000052408
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 73
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who do not meet the insurance coverage of the National Health Insurance in Japan for comprehensive genomic profiling testing 2. Patients with driver genetic alterations that are druggable by approved agents determined by multiplex companion diagnostics at the time of diagnosis 3. Patients who received more than one line of systemic treatment after the completion of standard treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients with actionable cancer genomic alterations detected using comprehensive genomic profiling tests.
- Secondary Outcome Measures
Name Time Method The proportion of patients with options of molecular-based recommended therapy (MBRT) determined by the molecular tumor board. The proportion of patients with druggable genomic alterations. The proportion of patients who received MBRT including clinical trials. The success rate of the comprehensive genomic profiling tests. Matching score of MBRT calculated using a matching score system. Response rate and progression-free survival in the treatment after comprehensive genomic profiling. Overall survival. Progression-free survival in MBRT.